CNR1 and fatty liver disease: A CB1R neutral antagonist AM6545 is equally effective as compared to its parent compound rimonabant at reversing hepatic steatosis but is less effective in reducing body weight, adiposity, insulin resistance, hyperleptinemia, and food intake [99].